Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 29

1.

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA.

J Clin Invest. 2011 Dec;121(12):4700-11. doi: 10.1172/JCI46382. Epub 2011 Nov 21.

PMID:
22105174
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

BRAF as a target for cancer therapy.

Dienstmann R, Tabernero J.

Anticancer Agents Med Chem. 2011 Mar;11(3):285-95. Review.

PMID:
21426297
[PubMed - indexed for MEDLINE]
3.

[The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].

Zafon C, Obiols G.

Endocrinol Nutr. 2009 Apr;56(4):176-86. doi: 10.1016/S1575-0922(09)70982-9. Epub 2009 Jun 11. Review. Spanish.

PMID:
19627734
[PubMed - indexed for MEDLINE]
4.

From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.

Albarel F, Conte-Devolx B, Oliver C.

Ann Endocrinol (Paris). 2012 Jun;73(3):155-64. doi: 10.1016/j.ando.2012.03.002. Epub 2012 Apr 13. Review.

PMID:
22503804
[PubMed - indexed for MEDLINE]
5.

BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.

Tang KT, Lee CH.

J Chin Med Assoc. 2010 Mar;73(3):113-28. doi: 10.1016/S1726-4901(10)70025-3. Review.

PMID:
20230995
[PubMed - indexed for MEDLINE]
6.

Role of BRAF in thyroid oncogenesis.

Caronia LM, Phay JE, Shah MH.

Clin Cancer Res. 2011 Dec 15;17(24):7511-7. doi: 10.1158/1078-0432.CCR-11-1155. Epub 2011 Sep 7. Review.

PMID:
21900390
[PubMed - indexed for MEDLINE]
Free Article
7.

BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Xing M.

Endocr Rev. 2007 Dec;28(7):742-62. Epub 2007 Oct 16. Review.

PMID:
17940185
[PubMed - indexed for MEDLINE]
8.

BRAF mutations in papillary thyroid carcinoma.

Wojciechowska K, Lewinski A.

Endocr Regul. 2006 Dec;40(4):129-38. Review.

PMID:
17201587
[PubMed - indexed for MEDLINE]
9.

Alterations of the BRAF gene in thyroid tumors.

Ciampi R, Nikiforov YE.

Endocr Pathol. 2005 Fall;16(3):163-72. Review.

PMID:
16299399
[PubMed - indexed for MEDLINE]
10.

Lessons from mouse models of thyroid cancer.

Kim CS, Zhu X.

Thyroid. 2009 Dec;19(12):1317-31. doi: 10.1089/thy.2009.1609. Review.

PMID:
20001715
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Clinical prognosis in BRAF-mutated PTC.

Puxeddu E, Moretti S.

Arq Bras Endocrinol Metabol. 2007 Jul;51(5):736-47. Review.

PMID:
17891237
[PubMed - indexed for MEDLINE]
Free Article
12.

Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer.

Sáez JM.

Anticancer Agents Med Chem. 2013 Mar;13(3):483-95. Review.

PMID:
22583421
[PubMed - indexed for MEDLINE]
13.

Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).

Nucera C, Goldfarb M, Hodin R, Parangi S.

Biochim Biophys Acta. 2009 Apr;1795(2):152-61. doi: 10.1016/j.bbcan.2009.01.003. Epub 2009 Jan 31. Review.

PMID:
19356676
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Vemurafenib for the treatment of melanoma.

Jordan EJ, Kelly CM.

Expert Opin Pharmacother. 2012 Dec;13(17):2533-43. doi: 10.1517/14656566.2012.737780. Epub 2012 Oct 24. Review.

PMID:
23094782
[PubMed - indexed for MEDLINE]
15.

BRAF signaling and targeted therapies in melanoma.

Dhomen N, Marais R.

Hematol Oncol Clin North Am. 2009 Jun;23(3):529-45, ix. doi: 10.1016/j.hoc.2009.04.001. Review.

PMID:
19464601
[PubMed - indexed for MEDLINE]
16.

[Progress of anti-tumor study based on BRAF].

Yan GR, Xu ZJ, Wang HY, Zhu WL.

Yao Xue Xue Bao. 2012 Dec;47(12):1567-74. Review. Chinese.

PMID:
23460959
[PubMed - indexed for MEDLINE]
17.

BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.

Nucera C, Lawler J, Parangi S.

Cancer Res. 2011 Apr 1;71(7):2417-22. doi: 10.1158/0008-5472.CAN-10-3844. Epub 2011 Mar 29. Review.

PMID:
21447745
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers.

Corcoran RB, Settleman J, Engelman JA.

Oncotarget. 2011 Apr;2(4):336-46. Review.

PMID:
21505228
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Update on thyroid cancer treatment.

Regalbuto C, Frasca F, Pellegriti G, Malandrino P, Marturano I, Di Carlo I, Pezzino V.

Future Oncol. 2012 Oct;8(10):1331-48. doi: 10.2217/fon.12.123. Review.

PMID:
23130931
[PubMed - indexed for MEDLINE]
20.

Gene methylation in thyroid tumorigenesis.

Xing M.

Endocrinology. 2007 Mar;148(3):948-53. Epub 2006 Aug 31. Review.

PMID:
16946009
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk